Randomized, Double Blind, Comparative Trial of the Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children of 6 and 11 Years Old Undergoing Minor Surgery

Boehringer Ingelheim0 sites122 target enrollmentMarch 2002

ConditionsPain

InterventionsMagnesium metamizol Placebo

Overview

Phase: Phase 4
Intervention: Magnesium metamizol
Conditions: Pain
Sponsor: Boehringer Ingelheim
Enrollment: 122
Primary Endpoint: Percentage of children requiring rescue medication
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

Study to assess the analgesic efficacy in the prevention of postoperative pain in children undergoing minor surgery (herniorraphy, tonsillectomy) and to assess the tolerability of Metamizol in this group of patients.

Registry

clinicaltrials.gov

Start Date

March 2002

End Date

March 2004

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Boehringer Ingelheim

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Children of either sex between 6 and 11 years of age
•Patients undergoing routine inguinal hernia repair or tonsillectomy
•Written informed consents by the guardian, according to the guidelines of Good Clinical Practice and current legislation
•The ability of the patient to understand and carry out the visual analogue scale assessments
•Patients with a physical status American Society of Anesthesiologist I or II class

Exclusion Criteria

•The use of any drug with analgesic properties in the 24 hours prior to the administration of the study drug
•Surgery with a foreseen duration over 60 minutes
•Patients with a nutritional index of less than 90 or greater than 120
•Patients with a body mass index which was not between the 3rd centile and the 97th centile for age
•Patients with any illness or malformation (except hernia) which, in the doctor's opinion, contraindicated the use of metamizol (aplastic anemia, agranulocytosis of a toxicological etiology, severe renal disease, etc.)
•Patients who have received in the previous 7 days or need currently anticoagulant treatment
•Significant allergy or known hypersensitivity to metamizol, its excipients and/or to other nonsteroidal antiinflammatory drugs
•Patients in whom the anesthetic regimen required by the protocol cannot be used
•Patients who have participated in another clinical trial in the past four weeks or are currently participating in another clinical trial
•Patients with any psychological disturbance which, in the investigator's opinion makes the patient unsuitable for inclusion in the trial

Arms & Interventions

Magnesium metamizol

Intervention: Magnesium metamizol

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Percentage of children requiring rescue medication

Time Frame: up to 4 hours after drug administration

Secondary Outcomes

Percentage of children who require rescue medication(up to 2 hours after drug administration)
Evaluation of the pain intensity by the patient by means of a Visual Analogue Scale (VAS)(up to 4 hours)
Time from drug administration, end of surgery and first patient's awake to the administration of rescue medication(up to 4 hours)
Evaluation of the pain intensity by the patient by means of a four points Verbal Rating Scale (VRS)(up to 4 hours)
Assessment of the state of the patient by the guardian by means of the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) test(up to 4 hours)
Assessment of the partial efficacy by the investigator by means of a four points VRS(up to 4 hours)
Assessment of the total efficacy by the investigator by means of a four points VRS(after 4 hours)
Number of patients with adverse events (AE)(up to 4 hours)
Number of withdrawals due to AEs(up to 4 hours)
Assessment of the total tolerability of the assigned treatment by the investigator by means of a four points VRS(after 4 hours)